Multiple Sclerosis (MS)

Clinical Trial Services

At BNAC, we support several key areas of ongoing research related to furthering the understanding of MS. These include quantitative brain atrophy, brain connectomics, optical coherence tomography, and radiotracers and PET imaging. Through these areas of research, we are committed to supporting regulatory approvals of medications and other interventions that use imaging outcomes in their trial design.

Brain Atrophy

This research helps discover the causes and progression of neurodegenerative changes in diseases like MS. Additionally, new measurement methods for real-world clinical use, such as the NeuroSTREAM platform, are created through this research. 

Brain Connectomics 

Our brain connectomics work uses state-of-the art structural and functional MRI connectivity measurements to help better understand neuroplasticity, recovery, and cognition.

Optical Coherence Tomography

Our optical coherence tomography research has shed new light on neurodegenerative central nervous system processes.

Radiotracers and PET Imaging

Our work with radiotracers and PET Imaging has expanded the understanding of molecular drivers in MS disease progression and pathology. 

Published Articles Related to MS

Featured Recent Clinical trials in MS

  • Zivadinov R, Dwyer MG, Carl E, Poole EM, Cavalier S, Briassouli P, Bergsland N. Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Ther Adv Neurol Dis 2020;13:1756286420970754. [Open article]
  • Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, Barnett Y, Barnett MH, Kyle KA, Zivadinov R, Ma KC, Milliken ST, Sutton IJ and Ma DDF (2019). "Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis." J Neurol Neurosurg Psychiatry 90(5): 514-521. [Open article]
  • Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C and Weinstock-Guttman B (2019). "Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis." Mult Scler Relat Disord 36: 101388. [Open article]
  • Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D and Weinstock-Guttman B (2019). "Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study." J Clin Med 8(3). [Open article]
  • Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M and Cohan S (2019). "Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study." J Comp Eff Res 8(5): 305-316. [Open article]
  • Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R and Group M-MS (2018). "Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study." CNS Drugs 32(1): 75-84. [Open article]

Read More Articles

Contact Our Team Today

If you need help managing a medical imaging trial related to MS speak with our team at BNAC. Our board-certified neuroimagers bring decades of experience to every trial we manage. Call us or fill out a form to learn more about our neuroimaging services today!

Contact Us